Rituximab for the first-line treatment of stage III-IV follicular lymphoma: (review of NICE technology appraisal guidance 110)

NICE technology appraisals [TA243] Published date:

This guidance updates and replaces NICE technology appraisal 110 (published in September 2006).

NICE recommends rituximab in combination with certain chemotherapies as a possible treatment for people with stage III–IV follicular lymphoma who haven’t been treated before (first-line treatment). Your doctor should talk to you about which chemotherapies can be used in combination with rituximab.

Who can have rituximab?

You should be able to have rituximab if all of the following apply:

  • you have symptoms
  • you have not had treatment before.

NICE has produced separate guidance on when rituximab can be offered to people with stage III–IV follicular lymphoma who have been treated before.

Why has NICE said this?

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS.

NICE recommended rituximab in combination with certain chemotherapies because it works better than other treatments available on the NHS. Although it costs more than some other treatments, this was justified by the additional benefits it provided.

Get involved